Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.52 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.52 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.52 |
| ▸ | PYGB | P11216 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121587 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13471593 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL10352861 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL18844756 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL18456970 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13126836 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL1755386 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL16327164 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL16870166 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL18406209 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828407-B2 | Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives | LIBRAGEN (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9669151-B2 | Therapeutic compositions for viral-associated disease states and methods of making and using same | ImMutriX Therapeutics, Inc. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | LIBRAGEN (FR) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | UGGT1, TYR, G6PD | LGALS1 267/4885LGALS3 600/4885LGALS9 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.